Bugworks Research gets $18mn funding as it scales up clinical research

Bugworks Research, a therapeutics company, on Wednesday announced it got $18 million financing in a funding round.

The Series B1 financing was led by Lightrock India and included existing investors the University of Tokyo Edge Capital (UTEC) Japan, Global Brain Corporation in Japan, 3ONE4Capital India, Acquipharma Holdings S.A, I.M Holdings B.V. and Featherlite Group India. Tejasvi Ravi, representing LightRock India will join the company’s Board of Directors. Kiran Mazumdar-Shaw, executive chairperson and founder of Biocon, is among the individual investors in the company.

This funding will support the company in its clinical development of BWC0977, a broad-spectrum anti-bacterial agent. Bugworks said it